Method of screening for arterial chlamydial granuloma

• US 5,424,187 A
• Filed: 06/12/1992
• Issued: 06/13/1995
• Est. Priority Date: 06/14/1991
• Status: Expired due to Term

• Current Assignee: Board of Regents of The University of Washington (University of Washington)
• Original Assignee: Allan Shor, Board of Regents of The University of Washington (University of Washington)
• Inventors: Kuo, Cho-chou, Shor, Allan
• Primary Examiner(s): Parr, Margaret
• Assistant Examiner(s): Schreiber, David
• Application Number:
  US07/898,905
• Time in Patent Office: 1,096 Days
• Field of Search: 435/4, 435/6, 435/7.1
• US Class Current: 435/6.16
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/65 Tetracyclines
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: G01N 33/56927 Chlamydia
• CPC Class Codes: G01N 33/571 for venereal disease, e.g. syphilis, gonorrhoea herpes G01N33/56994; chlamydia G01N33/56927

Abstract

Method of diagnosing arterial chlamydial granuloma by detecting in a biological sample both a first marker associated with Chlamydia pneumoniae and a second marker associated with arterial granuloma. Therapeutic composition for treating arterial chlamydial granulomatous disease, including an anti-Chlamydia pneumoniae agent and a granuloma inhibitor.

Claims

1. A method of screening for arterial chlamydial granuloma by detecting in a biological sample both a first marker associated with Chlamydia pneumoniae and a second marker associated with arterial granuloma.

2. The screening method of claim 1, wherein the first marker is a Chlamydia pneumoniae organism detected by electron microscopy, or the first marker is a Chlamydia pneumoniae antigen detected by immunohistochemical staining or immunoassay with a C. pneumoniae-specific binding partner, or the first marker is a C. pneumoniae-specific nucleotide sequence detected by nucleic acid hybridization with a C. pneumoniae-specific probe, or the first marker is a C. pneumoniae lipid detected by HPLC.

3. The screening method of claim 1, wherein the second marker is selected from among macrophage foam cells, fibrolipid deposits, and intimal smooth muscle cell necrosis detected by electron microscopy, or the second marker is an intimal smooth muscle-specific antigen detected by immunoassay, or the second marker is a granuloma-associated marker detected by immunoassay.